Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
Cantor Fitzgerald
Baxter
Fish and Richardson
QuintilesIMS
McKinsey
Harvard Business School
AstraZeneca
Accenture

Generated: August 21, 2017

DrugPatentWatch Database Preview

LESCOL Drug Profile

« Back to Dashboard

What is the patent landscape for Lescol, and what generic Lescol alternatives are available?

Lescol is a drug marketed by Novartis and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in LESCOL is fluvastatin sodium. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fluvastatin sodium profile page.

Summary for Tradename: LESCOL

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list116
Clinical Trials: see list8
Patent Applications: see list2,759
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LESCOL at DailyMed

Pharmacology for Tradename: LESCOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
LESCOL
fluvastatin sodium
CAPSULE;ORAL020261-001Dec 31, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Novartis
LESCOL
fluvastatin sodium
CAPSULE;ORAL020261-002Dec 31, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Novartis
LESCOL XL
fluvastatin sodium
TABLET, EXTENDED RELEASE;ORAL021192-001Oct 6, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LESCOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
LESCOL
fluvastatin sodium
CAPSULE;ORAL020261-001Dec 31, 1993► Subscribe► Subscribe
Novartis
LESCOL
fluvastatin sodium
CAPSULE;ORAL020261-002Dec 31, 1993► Subscribe► Subscribe
Novartis
LESCOL
fluvastatin sodium
CAPSULE;ORAL020261-001Dec 31, 1993► Subscribe► Subscribe
Novartis
LESCOL
fluvastatin sodium
CAPSULE;ORAL020261-002Dec 31, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LESCOL

Drugname Dosage Strength RLD Submissiondate
fluvastatinCapsules20 mg and 40 mgLescol6/4/2008
fluvastatin sodiumExtended-release Tablets80 mgLescol XL3/15/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
US Army
Daiichi Sankyo
Chubb
Cantor Fitzgerald
Merck
Dow
Federal Trade Commission
Teva
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot